Milestone Pharmaceuticals
MIST
27 hedge funds and large institutions have $114M invested in Milestone Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 3 closing their positions.
1,475% more call options, than puts
Call options by funds: $2.74M | Put options by funds: $174K
3% more capital invested
Capital invested by funds: $111M → $114M (+$3.13M)
0.65% less ownership
Funds ownership: 67.5% → 66.85% (-0.65%)
4% less funds holding
Funds holding: 28 → 27 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$833K |
| 2 |
EP
Eversept Partners
New York
|
+$640K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$147K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$59K |
| 5 |
State Street
Boston,
Massachusetts
|
+$21.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.3M |
| 2 |
Renaissance Technologies
New York
|
-$458K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$284K |
| 4 |
Two Sigma Advisers
New York
|
-$196K |
| 5 |
Morgan Stanley
New York
|
-$178K |
MIST Hedge Fund Activity: Q3 2021 in Review
27 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q3 2021, worth a combined $114M — up 2.8% from $111M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of MIST and 2 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 4 added.
The largest buyer was Pura Vida Investments, adding an estimated $833K. The largest seller was Ikarian Capital, cutting an estimated $1.3M.
- 27 institutional investors held Milestone Pharmaceuticals (MIST) as of Q3 2021, down from 28 in Q2 2021.
- Funds reported $114M of Milestone Pharmaceuticals stock for Q3 2021, up 2.8% quarter-over-quarter.
- 2 funds opened new Milestone Pharmaceuticals positions in Q3 2021 and 3 closed out, a net change of -1 holder.
- The largest Milestone Pharmaceuticals buyer in Q3 2021 was Pura Vida Investments, an estimated $833K added.
- The largest Milestone Pharmaceuticals seller in Q3 2021 was Ikarian Capital, an estimated $1.3M sold.
Based on aggregated 13F filings for Q3 2021.